Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis. 2018;77(11):1558e65.

Article  Google Scholar 

Harapas CR, Steiner A, Davidson S, et al. An update on autoinflammatory diseases: inflammasomopathies. Curr Rheumatol Rep. 2018;20(7):40.

Article  PubMed  Google Scholar 

Georgin-Lavialle S, Rodrigues F, Hentgen V, et al. Clinical overview of auto-inflammatory diseases. Rev Med Interne. 2018;39(4):214e32.

Google Scholar 

Davidson S, Steiner A, Harapas CR, et al. An update on autoinflammatory diseases: interferonopathies. Curr Rheumatol Rep. 2018;20(7):38.

Article  PubMed  Google Scholar 

Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron KS, Benseler S, Berard R, Broderick L, Dedeoglu F, Diebold M, Durrant KL, Ferguson P, Foell D, Hausmann J, Jones OY, Kastner DL, Lachmann HJ, Laxer RM, Rivera D, Ruperto N, Simon A, Twilt M, Frenkel J, Hoffman H, de Jesus AA, Kuemmerle-Deschner JB, Ozen S, Gattorno M, Goldbach-Mansky R, Demirkaya E. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis. 2022;81(7):907–21. https://doi.org/10.1136/annrheumdis-2021-221801.

Article  CAS  PubMed  Google Scholar 

Bettiol A, Lopalco G, Emmi G, Cantarini L, Urban ML, Vitale A, Denora N, Lopalco A, Cutrignelli A, Lopedota A, Venerito V, Fornaro M, Vannacci A, Rigante D, Cimaz R, Iannone F. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. Int J Mol Sci. 2019;20(8):1898. https://doi.org/10.3390/ijms20081898.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garg S, Wynne K, Omoyinmi E, Eleftheriou D, Brogan P. Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review. Rheumatol Adv Pract. 2019;3(1):rkz004. https://doi.org/10.1093/rap/rkz004.

Article  PubMed  PubMed Central  Google Scholar 

Lopalco G, Rigante D, Giannini M, Galeazzi M, Lapadula G, Iannone F, Cantarini L. Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol. 2016;34(3):531–8.

PubMed  Google Scholar 

Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, Lohse P, Koitchev A, Deuter C, Foell D, Benseler SM. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 2011Mar;63(3):840–9. https://doi.org/10.1002/art.30149.

Article  PubMed  Google Scholar 

Russo RA, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D, Edelsten C, Hawkins PN, Brogan PA. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology (Oxford). 2014;53(4):665–70. https://doi.org/10.1093/rheumatology/ket415.

Article  CAS  PubMed  Google Scholar 

Demirkaya E, Erer B, Ozen S, Ben-Chetrit E. Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review. Rheumatol Int. 2016;36(3):325–31. https://doi.org/10.1007/s00296-015-3408-9.

Article  CAS  PubMed  Google Scholar 

La Torre F, Caparello MC, Cimaz R. Canakinumab for the treatment of TNF-receptor associated periodic syndrome. Expert Rev Clin Immunol. 2017;13(6):513–23. https://doi.org/10.1080/1744666X.2017.1324783.

Article  PubMed  Google Scholar 

Betrains A, Staels F, Vanderschueren S. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. Semin Arthritis Rheum. 2020;50(4):636–42. https://doi.org/10.1016/j.semarthrit.2020.05.002.

Article  CAS  PubMed  Google Scholar 

Kacar M, Savic S, van der Hilst JCH. The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature. J Inflamm Res. 2020;9(13):141–9. https://doi.org/10.2147/JIR.S206204.

Article  Google Scholar 

Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review. Front Immunol. 2020;28(11):971. https://doi.org/10.3389/fimmu.2020.00971.

Article  CAS  Google Scholar 

Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis. 2013;5(6):315–29. https://doi.org/10.1177/1759720X13502629.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kullenberg T, Löfqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology. 2016;55(8):1499–506. https://doi.org/10.1093/rheumatology/kew208.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, Olivieri I, Goldoni M, Vitale A, Silvestri E, Prisco D, Lapadula G, Galeazzi M, Iannone F, Cantarini L. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–6. https://doi.org/10.1007/s10067-015-3004-0.

Article  PubMed  Google Scholar 

Jeyaratnam J, Simon A, Calvo I, Constantin T, et al. Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. Rheumatology. 2022;61(5):2088–94. https://doi.org/10.1093/rheumatology/keab696.

Article  CAS  PubMed  Google Scholar 

Néel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, Kyndt X, Puechal X, Weiller PJ, Decaux O, Ninet J, Hot A, Aouba A, Astudillo L, Berthelot JM, Bonnet F, Brisseau JM, Cador B, Closs-Prophette F, Dejoie T, de Korwin JD, Dhote R, Fior R, Grosbois B, Hachulla E, Hatron PY, Jardel H, Launay D, Lorleac’h A, Pottier P, Moulis G, Serratrice J, Smail A, Hamidou M. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev. 2014;13(10):1035–41. https://doi.org/10.1016/j.autrev.2014.08.031.

Article  CAS  PubMed  Google Scholar 

Cantarini L, Talarico R, Generali E, Emmi G, Lopalco G, Costa L, Silvestri E, Caso F, Franceschini R, Cimaz R, Iannone F, Galeazzi M, Selmi C. Safety profile of biologic agents for Behçet’s disease in a multicenter observational cohort study. Int J Rheum Dis. 2017;20(1):103–8. https://doi.org/10.1111/1756-185X.12732.

Article  CAS  PubMed  Google Scholar 

Kuemmerle-Deschner JB, Gautam R, George AT, Raza S, Lomax KG, Hur P. Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. RMD Open. 2020;6(2):e001227. https://doi.org/10.1136/rmdopen-2020-001227.

Article  PubMed  PubMed Central  Google Scholar 

Koga T, Sato S, Hagimori N, Yamamoto H, Ishimura M, Yasumi T, Kirino Y, Ikeda K, Yachie A, Migita K, Kishida D, Atsumi T, Kawakami A. A randomised, double-blind, placebo-controlled phase III trial on the efficacy and safety of tocilizumab in patients with familial Mediterranean fever. Clin Exp Rheumatol. 2022;40(8):1535–42. https://doi.org/10.55563/clinexprheumatol/fgx9vv.

Article  PubMed  Google Scholar 

Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2017;76(1):173–8.

Article  CAS  PubMed  Google Scholar 

Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. Trends Cancer. 2022;8(11):901–14. https://doi.org/10.1016/j.trecan.2022.07.002.

Article  CAS  PubMed  Google Scholar 

Binstadt BA, Nigrovic PA. The Conundrum of Lung Disease and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022;74(7):1122–31. https://doi.org/10.1002/art.42137.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erkens R, Esteban Y, Towe C, Schulert G, Vastert S. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease. Rheum Dis Clin North Am. 2021;47(4):585–606. https://doi.org/10.1016/j.rdc.2021.06.003.

Article  PubMed  Google Scholar 

Atas N, Eroglu GA, Sodan HN, Ozturk BO, Babaoglu H, Satis H, Karadeniz H, Guler AA, Salman RB, Goker B, Ozturk MA, Haznedaroglu S, Tufan A. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol. 2021;39(5):30–6. https://doi.org/10.55563/clinexprheumatol/815tdt.

Article  PubMed  Google Scholar 

de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JW, Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis. 2013;72(10):1634–8. https://doi.org/10.1136/annrheumdis-2012-202192.

Article  CAS  PubMed  Google Scholar 

Lachmann HJ, Lauwerys B, Miettunen P, Kallinich T, Jansson A, Rosner I, Manna R, Murias S, Savic S, Smeets S, De Benedetti F, Simon A. Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clin Exp Rheumatol. 2021;39(5):51–8. https://doi.org/10.55563/clinexprheumatol/e92f7o.

Article  PubMed  Google Scholar 

Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095–102. https://doi.org/10.1136/ard.2011.152728.

Article  CAS  PubMed  Google Scholar 

Ozen S, Ben-Cherit E, Foeldvari I, Amarilyo G, Ozdogan H, Vanderschueren S, Marzan K, Kahlenberg JM, Dekker E, De Benedetti F, Koné-Paut I. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Ann Rheum Dis. 2020;79(10):1362–9. https://doi.org/10.1136/annrheumdis-2020-217419.